DR. TOBENNA IGWEONU NWIZU M.D. NPI 1881879716

NPI Details

DR. Tobenna Igweonu Nwizu, M.D. is a hematology and oncology internal medicine in Rowlett, TX with 23 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Tobenna Igweonu Nwizu, M.D. NPI is 1881879716. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

7501 LAKEVIEW PKWY STE 100
ROWLETT, TX
ZIP 75088-330
Phone: (972) 412-2577
Fax: (972) 412-0398

The NPI 1881879716 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 1/9/2008 and was last updated on 3/17/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.